Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind — approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Clinical trials have shown weight loss results exceeding those of Semaglutide, making it one of the most effective pharmacological weight management tools available.
Quick facts
- Half-life
- ~5 days
- Administration
- Subcutaneous injection (weekly)
- Primary use
- Weight management, blood sugar regulation
How it works
Tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual action produces greater appetite suppression, improved insulin sensitivity, and enhanced fat metabolism compared to GLP-1 agonism alone.
Reported benefits
- Superior weight loss outcomes vs Semaglutide in head-to-head trials
- Improved blood glucose control and insulin sensitivity
- Reduced cardiovascular risk markers
- Dual GIP/GLP-1 mechanism for enhanced metabolic effect
Typical dosing protocol
Dosing
Starting at 2.5 mg/week, titrating up to 5–15 mg/week over several months under medical supervision
Cycle length
Long-term / ongoing under medical supervision
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Approved for medical use in the UK under prescription (Mounjaro). Common side effects include nausea, vomiting, and diarrhoea. Must only be used under medical supervision. Not for use in type 1 diabetes.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.